On Tuesday, Shares of Kite Pharma Inc (NASDAQ:KITE), lost -2.62% to $66.07.
Kite Pharma, stated financial results for the quarter ended June 30, 2015.
Highlights of Developments in Second Quarter 2015
- Commenced Kite’s Phase 1/2 clinical trial of KTE-C19, an anti-CD19 CAR T-cell therapy, for treatment of refractory, aggressive Non-Hodgkin’s Lymphoma (NHL).
- Presented clinical biomarker results at the 2015 American Society of Clinical Oncology Annual Meeting, which demonstrated that conditioning chemotherapy was associated with a noteworthyrise in homeostatic cytokines and chemokines, which could favor expansion, activation, and trafficking of CAR T cells.
- Declared our first TCR product candidate, targeting HPV-16 E6, that we plan to advance to a company-sponsored clinical trial.
- Reached an exclusive worldwide partnershipwith bluebird bio to advance second generation TCR products to treat HPV-associated cancers.
- Partnered with The Leukemia & Lymphoma Society to enhance the development of KTE-C19 in refractory, aggressive NHL and to launch CAR T-cell therapy educational programs.
- Accomplished construction of our clinical supply manufacturing facility in Santa Monica, California.
- Began construction on our manufacturing facility in El Segundo, California to support our commercial plans.
- Hosted our first Investor Day, which focused on our future research, clinical, and manufacturing plans.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
Shares of Energy Transfer Partners LP (NYSE:ETP), inclined 0.87% to $47.40, during its last trading session.
Sunoco LP, declared that it has accomplished the acquisition of Susser Holdings Corporation (SHC) from ETP Holdco Corporation and Heritage Holdings, Inc., wholly owned auxiliaries of Energy Transfer Partners, L.P. (ETP). The transaction is valued at about $1.93 billion. SUN paid $966.9 million in cash and issued ETP’s auxiliaries about 21.98 million SUN units, valued at about $966.9 million. In addition, there will be an exchange for 11 million SUN units owned by SHC for another 11 million new SUN units to a partner of ETP.
The transaction is predictable to be slightly accretive to SUN with respect to distributable cash flow in 2015 and significantly accretive thereafter.
Energy Transfer Partners, L.P. engages in the natural gas midstream, and intrastate transportation and storage businesses in the United States. The company’s Intrastate Transportation and Storage segment transports natural gas from various natural gas producing areas, in addition to through its ET fuel system and HPL system.
Finally, Abengoa Yield PLC (NASDAQ:ABY), ended its last trade with -2.07% loss, and closed at $22.71.
Abengoa Yield, declared its fourth asset acquisition:
Abengoa Yield has reached a definitive agreement with Abengoa to acquire Solaben 1/6, a 100 MW solar complex in Spain, which has been in operation since 2013, showing a solid operational track record and synergies with our existing portfolio.
Abengoa Yield plc owns a portfolio of renewable energy, conventional power, and electric transmission line contracted assets in North America, South America, and Europe. The company’s renewable energy assets comprise 2 solar power plants each with a gross capacity of 280 megawatts (MW) in the United States; 1 on-shore wind farm with a gross capacity of 50 MW in Uruguay; and 2 solar power plants each with a gross capacity of 50 MW in Spain.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
